Literature DB >> 21339906

Treatment strategies for tics in Tourette syndrome.

Clare M Eddy1, Hugh E Rickards, Andrea E Cavanna.   

Abstract

TOURETTE SYNDROME (TS) IS A CHRONIC NEURODEVELOPMENTAL DISORDER CHARACTERIZED BY TICS: repetitive, involuntary movements and vocalizations. These symptoms can have a significant impact on patients' daily functioning across many domains. Tics tend to be most severe in child and adolescent sufferers, so their presence has the potential to impact a period of life that is both critical for learning and is often associated with the experience of greater social tension and self-consciousness than adulthood. Furthermore, control over tics that lead to physical impairment or self-injurious behaviour is of vital importance in maintaining health and quality of life. There are numerous complicating factors in the prescription of treatment for tics, due to both the side effects associated with alleviating agents and patient characteristics, such as age and comorbid conditions. This review summarizes literature pertaining to the efficacy and safety of both traditionally prescribed and more modern medications. We also discuss the merits of behavioural and surgical techniques and highlight newer emerging treatments. Although treatment response is to some extent variable, there are a number of agents that are clearly useful as first-line treatments for TS. Other interventions may be of most benefit to patients exhibiting refractory tics or more specific symptom profiles.

Entities:  

Keywords:  Tourette syndrome; antipsychotics; botulinum toxin; deep brain stimulation; medication; neuroleptics; tics; treatment

Year:  2011        PMID: 21339906      PMCID: PMC3036957          DOI: 10.1177/1756285610390261

Source DB:  PubMed          Journal:  Ther Adv Neurol Disord        ISSN: 1756-2856            Impact factor:   6.570


  135 in total

1.  Effective open-label treatment of tourette's disorder with olanzapine.

Authors:  M Stamenkovic; S D Schindler; H N Aschauer; M De Zwaan; U Willinger; E Resinger; S Kasper
Journal:  Int Clin Psychopharmacol       Date:  2000-01       Impact factor: 1.659

2.  Sulpiride-induced tardive dyskinesia in a person with Gilles de la Tourette syndrome.

Authors:  V Eapen; C L Katona; T R Barnes; M M Robertson
Journal:  J Psychopharmacol       Date:  1993-01       Impact factor: 4.153

3.  Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder.

Authors:  F R Sallee; L Nesbitt; C Jackson; L Sine; G Sethuraman
Journal:  Am J Psychiatry       Date:  1997-08       Impact factor: 18.112

4.  Prolactin monitoring of haloperidol and pimozide treatment in children with Tourette's syndrome.

Authors:  F R Sallee; D Dougherty; G Sethuraman; N Vrindavanam
Journal:  Biol Psychiatry       Date:  1996-11-15       Impact factor: 13.382

5.  Olanzapine in the treatment of aggression and tics in children with Tourette's syndrome--a pilot study.

Authors:  Robyn J Stephens; Chris Bassel; Paul Sandor
Journal:  J Child Adolesc Psychopharmacol       Date:  2004       Impact factor: 2.576

6.  Fluphenazine and multifocal tic disorders.

Authors:  C G Goetz; C M Tanner; H L Klawans
Journal:  Arch Neurol       Date:  1984-03

7.  Aripiprazole for the treatment of Tourette's disorder.

Authors:  Prasad R Padala; S Faiz Qadri; Vishal Madaan
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

8.  Risperidone as a treatment for Tourette's syndrome.

Authors:  R D Bruun; C L Budman
Journal:  J Clin Psychiatry       Date:  1996-01       Impact factor: 4.384

9.  Aripiprazole in the pharmacotherapy of Gilles de la Tourette syndrome in adult patients.

Authors:  Wolfram Kawohl; Frank Schneider; Ingo Vernaleken; Irene Neuner
Journal:  World J Biol Psychiatry       Date:  2009       Impact factor: 4.132

10.  Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome.

Authors:  James T McCracken; Robert Suddath; Susanna Chang; Sarika Thakur; John Piacentini
Journal:  J Child Adolesc Psychopharmacol       Date:  2008-10       Impact factor: 2.576

View more
  35 in total

1.  Why so many deep brain stimulation targets in Tourette's syndrome? Toward a broadening of the definition of the syndrome.

Authors:  Mauro Porta; Christian Saleh; Edvin Zekaj; Carlotta Zanaboni Dina; Alberto R Bona; Domenico Servello
Journal:  J Neural Transm (Vienna)       Date:  2016-01-06       Impact factor: 3.575

2.  Tourette syndrome associated with attention deficit hyperactivity disorder: The impact of tics and psychopharmacological treatment options.

Authors:  Olumide O Oluwabusi; Susan Parke; Paul J Ambrosini
Journal:  World J Clin Pediatr       Date:  2016-02-08

Review 3.  Abnormal neuronal activity in Tourette syndrome and its modulation using deep brain stimulation.

Authors:  Michal Israelashvili; Yocheved Loewenstern; Izhar Bar-Gad
Journal:  J Neurophysiol       Date:  2015-04-29       Impact factor: 2.714

4.  Conservation law for self-paced movements.

Authors:  Dongsung Huh; Terrence J Sejnowski
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-14       Impact factor: 11.205

Review 5.  Cervical spondylotic myelopathy caused by violent motor tics in a child with Tourette syndrome.

Authors:  Da-Young Ko; Seung-Ki Kim; Jong-Hee Chae; Kyu-Chang Wang; Ji Hoon Phi
Journal:  Childs Nerv Syst       Date:  2012-10-07       Impact factor: 1.475

6.  Aripiprazole versus risperidone for treating children and adolescents with tic disorder: a randomized double blind clinical trial.

Authors:  Ahmad Ghanizadeh; Alireza Haghighi
Journal:  Child Psychiatry Hum Dev       Date:  2014-10

Review 7.  The pharmacology of Tourette syndrome.

Authors:  Roji Thomas; Andrea E Cavanna
Journal:  J Neural Transm (Vienna)       Date:  2013-01-30       Impact factor: 3.575

8.  Prescription Benzodiazepine Use in Privately Insured U.S. Children and Adolescents.

Authors:  Greta A Bushnell; Stephen Crystal; Mark Olfson
Journal:  Am J Prev Med       Date:  2019-12       Impact factor: 5.043

9.  Treatment use among children with Tourette syndrome living in the United States, 2014.

Authors:  Sara Beth Wolicki; Rebecca H Bitsko; Joseph R Holbrook; Melissa L Danielson; Benjamin Zablotsky; Lawrence Scahill; John T Walkup; Douglas W Woods; Jonathan W Mink
Journal:  Psychiatry Res       Date:  2020-08-18       Impact factor: 3.222

10.  Outpatient Treatment of Tic Disorders Among Children and Adults.

Authors:  Joseph L Smith; Sean Gregory; Nicole McBride; Tanya K Murphy; Eric A Storch
Journal:  Mov Disord Clin Pract       Date:  2017-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.